MA34735B1 - Compositions thérapeutiques comprenant un hydrochlorure de rilpivirine et un fumarate de ténofovir disoproxil - Google Patents

Compositions thérapeutiques comprenant un hydrochlorure de rilpivirine et un fumarate de ténofovir disoproxil

Info

Publication number
MA34735B1
MA34735B1 MA36010A MA36010A MA34735B1 MA 34735 B1 MA34735 B1 MA 34735B1 MA 36010 A MA36010 A MA 36010A MA 36010 A MA36010 A MA 36010A MA 34735 B1 MA34735 B1 MA 34735B1
Authority
MA
Morocco
Prior art keywords
tenofovir disoproxil
disoproxil fumarate
therapeutic compositions
rilpivirine hydrochloride
hydrochloride
Prior art date
Application number
MA36010A
Other languages
English (en)
Inventor
Reza Oliyai
Lauren Wiser
Mark Menning
Original Assignee
Janssen R & D Ireland
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45094284&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34735(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen R & D Ireland, Gilead Sciences Inc filed Critical Janssen R & D Ireland
Publication of MA34735B1 publication Critical patent/MA34735B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des comprimés multicouches qui contiennent un hydrochlorure de rilpivirine, un emtricitabine et un fumarate de ténofovir disoproxil. Les comprimés sont utilisés pour traiter le VIH.
MA36010A 2010-11-19 2013-06-14 Compositions thérapeutiques comprenant un hydrochlorure de rilpivirine et un fumarate de ténofovir disoproxil MA34735B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41560010P 2010-11-19 2010-11-19
PCT/US2011/061515 WO2012068535A1 (fr) 2010-11-19 2011-11-18 Compositions thérapeutiques comprenant un hydrochlorure de rilpivirine et un fumarate de ténofovir disoproxil

Publications (1)

Publication Number Publication Date
MA34735B1 true MA34735B1 (fr) 2013-12-03

Family

ID=45094284

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36010A MA34735B1 (fr) 2010-11-19 2013-06-14 Compositions thérapeutiques comprenant un hydrochlorure de rilpivirine et un fumarate de ténofovir disoproxil

Country Status (36)

Country Link
US (1) US10857102B2 (fr)
EP (2) EP2826466A1 (fr)
JP (2) JP2014500261A (fr)
KR (1) KR101923103B1 (fr)
CN (2) CN103491948B (fr)
AP (1) AP3816A (fr)
AR (2) AR084500A1 (fr)
AU (3) AU2011329642B2 (fr)
BR (1) BR112013012245B1 (fr)
CA (1) CA2818097C (fr)
CL (1) CL2013001402A1 (fr)
CO (1) CO6761300A2 (fr)
CR (1) CR20130293A (fr)
DK (1) DK2640362T4 (fr)
EA (2) EA201691695A1 (fr)
EC (2) ECSP13012700A (fr)
ES (1) ES2524408T5 (fr)
HK (1) HK1206592A1 (fr)
HR (1) HRP20140946T1 (fr)
IL (1) IL226300B (fr)
MA (1) MA34735B1 (fr)
ME (1) ME01980B (fr)
MX (1) MX347512B (fr)
MY (1) MY185604A (fr)
NZ (1) NZ610729A (fr)
PE (3) PE20211657A1 (fr)
PH (1) PH12013501002A1 (fr)
PL (1) PL2640362T5 (fr)
PT (1) PT2640362E (fr)
RS (1) RS53691B1 (fr)
SG (3) SG190333A1 (fr)
SM (1) SMT201400150B (fr)
TW (1) TWI556840B (fr)
UA (1) UA114075C2 (fr)
WO (1) WO2012068535A1 (fr)
ZA (1) ZA201304481B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1583542T3 (da) 2003-01-14 2008-09-22 Gilead Sciences Inc Sammensætninger og fremgangsmåder til antiviral kombinationsterapi
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
JP2014500261A (ja) 2010-11-19 2014-01-09 ギリアード サイエンシーズ， インコーポレイテッド リルピビリンＨＣｌおよびフマル酸テノホビルジソプロキシルを含有する治療用組成物
ES2608871T5 (es) 2011-08-16 2024-04-04 Gilead Sciences Inc Alafenamide hemifumarate de tenofovir
CA2779052A1 (fr) * 2012-05-31 2013-11-30 Pharmascience Inc. Composition pharmaceutique d'antecavir et processus de fabrication
EA030003B1 (ru) 2012-12-21 2018-06-29 Джилид Сайэнс, Инк. Полициклическое карбамоилпиридоновое соединение и его фармацевтическое применение для лечения вич-инфекции
WO2015014737A1 (fr) * 2013-07-29 2015-02-05 Sanovel Ilac Sanayi Ve Ticaret A.S. Formulations pour comprimés multicouches comprenant du tenofovir et de l'entécavir
CZ2013985A3 (cs) * 2013-12-09 2015-06-17 Zentiva, K.S. Stabilní farmaceutická kompozice obsahující tenofovir disoproxil fumarát
WO2015152433A1 (fr) * 2014-03-31 2015-10-08 Hanmi Pharm. Co., Ltd. Dispersion solide amorphe comprenant du paclitaxel, comprimé la comprenant, et son procédé de préparation
JP7381190B2 (ja) 2014-12-26 2023-11-15 エモリー・ユニバーシテイ Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途
US9839212B2 (en) 2015-04-16 2017-12-12 Bio-Lab, Inc. Multicomponent and multilayer compacted tablets
CA2921336A1 (fr) * 2015-06-30 2016-12-30 Gilead Sciences, Inc. Formulations pharmaceutiques
KR20170003063A (ko) * 2015-06-30 2017-01-09 한미약품 주식회사 테노포비어 디소프록실 함유 경구용 고형제제 및 그 제조방법
WO2017083304A1 (fr) 2015-11-09 2017-05-18 Gilead Sciences, Inc. Compositions thérapeutiques pour le traitement du virus de l'immunodéficience humaine
EP3439639A1 (fr) * 2016-04-08 2019-02-13 Shionogi & Co., Ltd. Forme posologique solide stabilisée
TR201617448A2 (tr) * 2016-11-29 2018-06-21 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Tenofovi̇r ve emtri̇si̇tabi̇n i̇çeren kati oral farmasöti̇k bi̇leşi̇mler
US10561614B2 (en) * 2017-01-27 2020-02-18 Steerlife India Private Limited Tenofovir granules
CN110958883A (zh) * 2017-06-30 2020-04-03 Viiv保健公司 组合及其用途和疗法
PT3706762T (pt) 2017-12-07 2024-12-05 Univ Emory N4-hidroxicitidina e derivados e utilizações antivirais relacionadas com os mesmos
JP2022538338A (ja) * 2019-07-03 2022-09-01 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー リルピビリンを用いて小児患者におけるｈｉｖを治療する方法
CN112137981A (zh) * 2020-11-02 2020-12-29 成都晶富医药科技有限公司 富马酸丙酚替诺福韦片及其制备工艺
WO2024211882A1 (fr) * 2023-04-07 2024-10-10 Navinta, Llc Compositions stables de rilpivirine hcl en combinaison avec d'autres agents anti-retroviraux
CN119174735A (zh) * 2024-09-03 2024-12-24 安徽贝克生物制药有限公司 一种含利匹韦林的复方片及制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL100965A (en) 1991-02-22 1999-12-31 Univ Emory 2-Hydroxymethyl-5-(5-fluorocytosin-l-yl)-1,3-oxathiolane its resolution and pharmaceutical compositions containing it
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
AU2002359518A1 (en) 2001-11-27 2003-06-10 Bristol-Myers Squibb Company Efavirenz tablet formulation having unique biopharmaceutical characteristics
DK1583542T3 (da) 2003-01-14 2008-09-22 Gilead Sciences Inc Sammensætninger og fremgangsmåder til antiviral kombinationsterapi
AU2005279158C1 (en) 2004-09-02 2010-12-16 Janssen Pharmaceutica N.V. Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile
BRPI0514871A (pt) 2004-09-02 2008-06-24 Janssen Pharmaceutica Nv cloridrato de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]-2-pirimidi nil]amino] benzonitrila
TWI375560B (en) * 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) * 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
AU2006304180A1 (en) 2005-10-14 2007-04-26 Microdose Therapeutx, Inc. Pharmaceutical packaging of an oral dosage combination
RU2008128424A (ru) 2005-12-14 2010-01-20 Сипла Лимитед (In) Фармацевтическая комбинация, включающая нуклеотидный и нуклеозидный ингибиторы обратной транскриптазы (такие как тенофовир и ламивудин) в различных частях дозы
MX2009008935A (es) * 2007-02-23 2009-11-02 Gilead Sciences Inc Moduladores de las propiedades farmacocineticas de productos terapeuticos.
US20080286344A1 (en) 2007-05-16 2008-11-20 Olivia Darmuzey Solid form
WO2008140461A1 (fr) 2007-05-16 2008-11-20 Fmc Corporation Forme solide
AU2008253803A1 (en) * 2007-05-22 2008-11-27 Ultimorphix Technolgies B.V. Tenofovir disoproxil hemi-fumaric acid Co-crystal
WO2009037449A1 (fr) 2007-09-18 2009-03-26 Cipla Limited Compositions pharmaceutiques solides comprenant un ou plusieurs inhibiteurs du virus de l'herpès et un ou plusieurs inhibiteurs de la transcriptase inverse
WO2009106960A2 (fr) 2008-02-27 2009-09-03 Aurobindo Pharma Limited Compositions stables de lamivudine, de ténofovir et d'éfavirenz
MX2010011963A (es) 2008-05-02 2010-12-06 Gilead Sciences Inc Uso de particulas trasportadoras solidas para mejorar la capacidad de procesamiento de un agente farmaceutico.
EP2393485B1 (fr) 2009-02-06 2015-07-29 Gilead Sciences, Inc. Comprimé bicouche contenant de l'elvitegravir, du cobicistat, de l'emtricitabine et du tenofovir
CN102596958A (zh) 2009-09-21 2012-07-18 吉里德科学公司 用于抗病毒治疗的2’-氟代carba-核苷类似物
WO2011077100A1 (fr) 2009-12-24 2011-06-30 Cipla Limited Composition antirétrovirale
JP2014500261A (ja) 2010-11-19 2014-01-09 ギリアード サイエンシーズ， インコーポレイテッド リルピビリンＨＣｌおよびフマル酸テノホビルジソプロキシルを含有する治療用組成物

Also Published As

Publication number Publication date
SMT201400150B (it) 2015-01-15
AU2016208417A1 (en) 2016-08-18
JP2015131853A (ja) 2015-07-23
PT2640362E (pt) 2014-11-28
AU2016208417B2 (en) 2018-04-05
DK2640362T3 (en) 2014-12-01
PE20211657A1 (es) 2021-08-24
SG10201912527XA (en) 2020-02-27
ME01980B (fr) 2015-05-20
ZA201304481B (en) 2022-03-30
PE20170521A1 (es) 2017-05-27
CN103491948B (zh) 2016-11-02
EA201691695A1 (ru) 2017-11-30
CL2013001402A1 (es) 2013-12-27
KR20140037799A (ko) 2014-03-27
PE20140163A1 (es) 2014-02-08
EP2640362B1 (fr) 2014-09-10
IL226300B (en) 2019-05-30
NZ610729A (en) 2015-10-30
DK2640362T4 (da) 2022-03-07
ECSP19078196A (es) 2019-11-30
EA025852B1 (ru) 2017-02-28
MX347512B (es) 2017-04-28
UA114075C2 (xx) 2017-04-25
SG190333A1 (en) 2013-06-28
AU2011329642A1 (en) 2013-05-02
CA2818097C (fr) 2019-07-30
CA2818097A1 (fr) 2012-05-24
AU2018202635A1 (en) 2018-05-10
SG10201509521WA (en) 2015-12-30
CR20130293A (es) 2013-10-03
US20130243857A1 (en) 2013-09-19
CN103491948A (zh) 2014-01-01
HRP20140946T1 (hr) 2015-02-13
ES2524408T3 (es) 2014-12-09
TW201238612A (en) 2012-10-01
EA201390651A1 (ru) 2013-11-29
JP6138851B2 (ja) 2017-05-31
BR112013012245A2 (pt) 2016-08-09
EP2640362B2 (fr) 2021-12-01
EP2826466A1 (fr) 2015-01-21
MY185604A (en) 2021-05-25
US10857102B2 (en) 2020-12-08
CO6761300A2 (es) 2013-09-30
EP2640362A1 (fr) 2013-09-25
MX2013005669A (es) 2013-11-04
PL2640362T5 (pl) 2022-05-02
KR101923103B1 (ko) 2018-11-28
HK1206592A1 (en) 2016-01-15
AP2013006931A0 (en) 2013-06-30
AU2011329642B2 (en) 2016-08-11
CN106511357A (zh) 2017-03-22
BR112013012245B1 (pt) 2022-09-27
RS53691B1 (sr) 2015-04-30
AR123409A2 (es) 2022-11-30
PH12013501002A1 (en) 2013-09-09
AP3816A (en) 2016-09-30
HK1190064A1 (en) 2014-06-27
PL2640362T3 (pl) 2015-03-31
TWI556840B (zh) 2016-11-11
ECSP13012700A (es) 2013-08-30
WO2012068535A1 (fr) 2012-05-24
JP2014500261A (ja) 2014-01-09
AR084500A1 (es) 2013-05-22
ES2524408T5 (es) 2022-04-25

Similar Documents

Publication Publication Date Title
MA34735B1 (fr) Compositions thérapeutiques comprenant un hydrochlorure de rilpivirine et un fumarate de ténofovir disoproxil
PH12017502431A1 (en) Pharmaceutical formulations comprising tenofovir and emtrictabine
SA519402217B1 (ar) مثبطات إيميدازو بيرازين لكيناز تيروسين بروتون
JOP20190041A1 (ar) مركبات وتركيبات كمثبطات لمستقبلات شبيهة بالتول إندوسومية
CY1119766T1 (el) Νεοι ρυθμιστες κινασης βενζοπυρανιου
MA43187A (fr) Formulations sous-cutanée d'anticorps anti-cd38 et leurs utilisations
MA44890A (fr) Compositions comprenant des souches bactériennes
MA44322A (fr) Compositions comprenant des souches bactériennes
MY191357A (en) Sustained-release dosage forms of ruxolitinib
MA42471A (fr) Compositions comprenant des souches bactériennes
MX2017016802A (es) Formulaciones farmaceuticas.
MX2012003555A (es) Composicion farmaceutica que comprende acido graso omega-3 y derivado hidroxi de una estatina y metodos para usar la misma.
MA39094A1 (fr) Polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers
MA37840A3 (fr) Immunoconjugués comprenant des anticorps anti-cd79b
PT3609886T (pt) Análogos de benzoazepina como agentes inibidores para tirosina quinase de bruton
UA113538C2 (xx) Фторметил-5,6-дигідро-4h-$1,3]оксазини
EP4424373A3 (fr) Compositions pharmaceutiques contenant de la doravirine, du fumarate de ténofovir disoproxil et de lamivudine
EA201991286A1 (ru) Твердая фармацевтическая композиция для перорального применения, содержащая тенофовир и эмтрицитабин
ZA201906153B (en) Pharmaceutical compositions for combination therapy
MX2017010323A (es) Formulaciones farmaceuticas de inhibidor de esterasa c1.
FR2990843B1 (fr) Dispositif d'attache implantable, implant pour le traitement des prolapsus de la statique pelvienne comportant un tel dispositif et kit comprenant ledit dispositif.
CY1118255T1 (el) Υποκατεστημενα 6-αμινο-νικοτιναμιδια τα οποια φερουν μια ομαδα που περιεχει οη ως διαμορφωτες των kcnq2/3
JOP20170198A1 (ar) صيغ صيدلية تشتمل على تينوفوفير و إيمترايسيتابين
CY1116115T1 (el) Θεραπευτικες συνθεσεις οι οποιες αποτελουνται απο ριλπιβιρινη hcl και δισοπροξιλικη φουμαρικη τενοφοβιρη
MA46980A (fr) Compositions comprenant des souches bactériennes